医学
糖尿病前期
四分位间距
危险系数
糖尿病
内科学
比例危险模型
队列
队列研究
人口
2型糖尿病
置信区间
内分泌学
环境卫生
作者
Hangkuan Liu,Shuohua Chen,Ziping Li,Aijun Xing,Yan Liu,Jiaxin Yu,Dai Li,Yongle Li,Xin Zhou,Qing Yang,Shouling Wu,Ping Lei
出处
期刊:Age and Ageing
[Oxford University Press]
日期:2022-06-01
卷期号:51 (6)
被引量:3
标识
DOI:10.1093/ageing/afac109
摘要
Ageing and diabetes are growing global health burdens. The current understanding of cardiovascular disease (CVD) and mortality risk across the glycaemic spectrum in older populations is limited.This study sought to characterise CVD and all-cause mortality risk across the glycaemic spectrum among Chinese adults aged 75 years or older in a community-based setting over10 years.The 3,989 adults in the Kailuan Study were aged over 75 years (median age was 79 years [interquartile range: 76-82]; 2,785 normoglycaemic, 691 prediabetic and 513 diabetic, determined by fasting blood glucose levels) at baseline, predominantly male (92.9% male) and followed until December 2019. Time-varying Cox regression and competing-risk models were used to examine the hazard ratio (HR) of incident CVD and mortality across the glycaemic exposures.During median follow-up of 11.3 years, 433 first CVD and 2,222 deaths were recorded. Compared with normoglycaemia, multivariable-adjusted models revealed the following: (i) prediabetes was not associated with future risks for CVD (HR: 1.17; 95% CI 0.82-1.69) and all-cause mortality (HR 1.06; 95% CI 0.70-1.60); (ii) diabetes-associated enhanced risks for CVD and all-cause mortality were mainly confined to those exhibiting low-grade inflammation (high-sensitivity C-reactive protein ≥2.0 mg/L) levels. The results were consistent after multiple sensitivity analyses.Among a male-predominant Chinese population aged 75 years or older, compared with normoglycaemic participants, prediabetes was not associated with an enhanced 10-year CVD and all-cause mortality risk, and diabetes-associated enhanced 10-year risk was mainly confined to individuals exhibiting low-grade inflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI